US4465624A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for producing erythropoietin
Assignee: Fuso Pharmaceutical Industries Ltd
•
Filing: 1983-12-09
•
Granted: 1984-08-14
•
Expires: 2003-12-09
Abstract
Abstract Disclosed herein is a process for producing erythropoietin, comprising bringing a material containing erythropoietin into contact with an adsorbent having a monoclonal anti-erythropoietin antibody, adsorbing erythropoietin on the adsorbent, and eluting the absorbed erythropoietin from the adsorbent.
Inventors
- 👤 Hideo Chiba
- 👤 Ryuzo Sasaki
- 👤 Masatsugu Ueda
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:44
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/22; C07K14/00; C07K14/435; C07K14/475; C07K14/505; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/808; Y10S530/809; Y10S530/81; Y10S530/812; Y10S530/813; Y10S530/814
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
80 words
A process for producing highly pure erythropoietin from a material containing erythropoietin, which comprises bringing said material containing erythropoietin into contact with an adsorbent having monoclonal anti-erythropoietin antibody, said monoclonal anti-erythropoietin antibody being prepared from hybridoma in which said hybridoma is obtained by cell-fusing a myeloma cell and a spleen cell of an experimental animal immunized by erythropoietin, adsorbing said erythropoietin on said monoclonal anti-erythropoietin antibody in said adsorbent, eluting said erythropoietin from said adsorbent, and collecting the eluted erythropoietin.
Claim 2
Dependent Claim
80 words
A process for producing highly pure erythropoietin from a material containing erythropoietin, which comprises bringing said material containing erythropoietin into contact with an adsorbent having monoclonal anti-erythropoietin antibody, said monoclonal anti-erythropoietin antibody being prepared from hybridoma in which said hybridoma is obtained by cell-fusing a myeloma cell and a spleen cell of an experimental animal immunized by erythropoietin, adsorbing said erythropoietin on said monoclonal anti-erythropoietin antibody in said adsorbent, eluting said erythropoietin from said adsorbent, and collecting the eluted erythropoietin.
Claim 3
Dependent Claim
21 words
a process according to claim 1, in which the adsorbent is made from the monoclonal anti-erythropoietin antibody and Affi-Gel or Sephadex.
Claim 4
Dependent Claim
23 words
A process according to claim 1 or 2, in which the material containing erythropoietin is passed through a column packed with the adsorbent.
Claim 5
Dependent Claim
26 words
A process according to claim 1, in which the adsorbed erythropoietin is eluted with a mixture of acetic acid and an aqueous solution of sodium chloride.
Claim 6
Dependent Claim
25 words
A process according to claim 1, in which the once used adsorbent is regenerated and the regenerated adsorbent is repeatedly used in the adsorbing step.
References Cited (Backward Citations)
US3865801A
Cited
US4377513A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-14 | 1988-02-13 | 1988-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-14 | 1992-02-13 | 1992-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-14 | 1996-02-13 | 1996-08-14 | $7700.00 | Window Closed / Lapsed |